Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5661MR)

This product GTTS-WQ5661MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5661MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9206MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ1145MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ3034MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ10883MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ7190MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ9544MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ11059MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ9948MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW